Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab Real-World Study in Chinese Adults with Moderate-to-Severe Atopic Dermatitis
ChiCTR2600130135Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of spesolimab in atopic dermatitis (AD), sponsored by Huashan Hospital. Primary endpoint: Proportion of patients achieving EASI-75 at Week 16. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
spesolimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2600130135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130135.